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Paris, France 2019 — 
several days ago, the re-
sults of the ISAR-REACT 
5 were finally presented 
during the European So-
ciety of Cardiology ESC 
Congress 2019 in Paris. 
The Intracoronary Stent-
ing and Antithrombotic 
Regimen: Rapid Early Ac-
tion for Coronary Treat-
ment (ISAR-REACT) 5 trial was an investiga-
tor-initiated, phase 4, multicenter, randomized, 
open-label trial [1]. The study was designed to 
demonstrate the superiority of ticagrelor vs. prasu-
grel; in contrast, the main finding of this trial was 
the reported superiority of prasugrel over tica-
grelor with respect to the composite endpoint of 
death, myocardial infarction, or stroke 1 year after 
randomization, in patients with acute coronary 
syndromes. Reduced incidence of the composite 
endpoint in the prasugrel arm was not associated 
with an increased risk of bleeding. 
However, quite the opposite results were 
commonly expected based on the existing body 
of evidence from the previously published trials. 
The ISAR-REACT 5 trial did not directly 
compare two antiplatelet agents, but rather dif-
ferent  antiplatelet strategies mimicking the ESC 
guidelines, but not quite so [2–4]. Thus, the results 
do not reflect current clinical practice.
In our opinion, the study design and its orga-
nization lead to a bias that is difficult to estimate 
due to several reasons. Both the open-label design 
of the trial and the fact that it was performed only 
in two countries with a disproportion of enroll-
ing centers (21 centers 
in Germany and 2 centers 
in Italy) could have had 
some, however probably 
minor, impact on the out-
comes. On the other hand, 
the adherence to the trial 
medication could have had 
much more influence on 
the results. The stated 
non-adherence to the 
treatment of 0.9% in prasugrel arm and 0.4% in 
ticagrelor arm seem to be unequivocally under-
estimated as patients were followed up mainly by 
telephone only (83% of contacts), at hospital or by 
outpatient visit (10%), or by using structured fol-
low-up letter (7%). Moreover, after the in-hospital 
phase of the trial commercially available ticagrelor 
or prasugrel were prescribed by the physician and 
had to be purchased by the patients themselves. 
No specific method for adherence evaluation, i.e. 
medication event monitoring systems, pill count, 
or drug availability according to the purchase of 
prescribed drugs etc., was reported. As the patient-
reported, drug intake was previously shown to be 
misleading, the true adherence to trial medication 
was probably much lower than that reported by the 
authors [5, 6]. 
The intention-to-treat analysis, i.e. with the 
inclusion of all patients according to the randomly 
assigned trial group, irrespective of the actual 
treatment received, is a widely accepted method 
for such kind of clinical studies. In this particular 
trial, however, such design might have led to 
serious distortion of the results, as only 1602 of 
2012 and 1596 of 2006 subjects in ticagrelor and 
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prasugrel groups, respectively, were discharged 
from the hospital on the allocated medication. 
Moreover, additional 243 and 199 patients in each 
arm, respectively, discontinued study medication 
after discharge, and finally, 19 and 18 patients were 
lost to follow-up in each group. The intention-to-
-treat principle applied in the ISAR-REACT 5 has 
led to the inclusion of at least 1262 patients in final 
analysis, who were not treated with the assigned 
medication (653 of 2012 subjects (32.5%) and 609 
of 2006 subjects (30.4%) in ticagrelor and prasugrel 
arms, respectively). 
A primary endpoint (the composite endpoint 
of all-cause death, myocardial infarction, or stroke) 
at 1 year after randomization, occurred in 184 of 
2012 patients (9.3%) in the ticagrelor group and in 
137 of 2006 patients (6.9%) in the prasugrel group 
(HR, 1.36; 95% CI, 1.09 to 1.70; P = 0.006). Tak-
ing into account that the analysis of 4018 patients 
included 1262 (31.4%) who were supposed to be on 
study medication, whereas they were not treated 
according to the study protocol, the absolute dif-
ference in primary endpoint incidence of 47 events 
can hardly be considered relevant. 
In the analysis of the primary endpoint oc-
currence among subjects discharged on the study 
medication (1602 patients on ticagrelor and 1596 
patients on prasugrel) in the period from discharge 
to the time of discontinuation of treatment or end of 
follow-up (“on treatment” analysis), the difference 
between the arms has been shown not to be sig-
nificant (92 events in the ticagrelor group and 71 in 
the prasugrel group; HR, 1.34; 95% CI, 0.98–1.82). 
The observed bleeding rates are also the 
subject of questions. In the modified intention-to-
treat analysis the safety endpoint (major bleeding 
BARC type 3 through 5) was observed in 95 pa-
tients (5.4%) in ticagrelor arm and in 80 patients 
(4.8%) in the prasugrel arm (HR, 1.12; 95% CI, 
0.83 to 1.51; P = 0.46). The absolute difference 
of 15 events between the groups, while as many 
as 233 of 2006 patients (11.6%) from prasugrel 
group and only 23 of 2012 patients (1.1%) from the 
ticagrelor group were excluded from this analysis 
without any justification, is difficult to interpret. 
Thus, the result of both efficacy and safety needs 
to be carefully validated.
In conclusion, the ISAR-REACT 5 trial, in-
deed instead of providing answers, rather rises 
questions. Trying to answer the title question: 
“ISAR-REACT 5 — What have we learned?” we 
found ourselves in trouble, as we can not provide 
any definitive statement.
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